No approved hantavirus vaccine exists in the United States or most Western countries as of mid-2026, with development candidates remaining in preclinical or early Phase 1 stages amid the virus’s low incidence. Recent outbreaks, including a 2026 cruise ship event, have spotlighted the gap but have not accelerated any candidate into pivotal efficacy trials required for licensure. Vaccine timelines typically span years from promising animal data—such as recent mRNA or DNA constructs showing neutralizing antibodies in models—to regulatory approval, and no large-scale human studies are underway to meet 2026 thresholds. Traders assign 94.5% probability to “No” based on this evidence, though an unexpected emergency authorization or rapid regulatory fast-track could shift odds if case surges intensify.